Objective, Real-World Sleep Measures Strengthen Clinical Insights

Overview

Chronic insomnia disorder, marked by ongoing difficulty falling or staying asleep, can have a profound impact on health, daily functioning, and overall quality of life. While cognitive behavioral therapy remains the gold-standard treatment, many patients with chronic insomnia rely on pharmacological options when access is limited or symptoms persist. 

Zelira Therapeutics conducted a randomized controlled trial to evaluate the effectiveness of a cannabinoid-based therapy (ZTL-101) for chronic insomnia. This study highlights how combining patient-reported and objective, real-world digital measures can deliver a more complete picture of treatment impact.